Nevertheless, recent data from the ERA-EDTA registry revealed that absolute case-specific excess mortality due to atheromatous CVD present a decreasing trend from 2007 to 2015 in patients on renal replacement therapy [ 146 ].
1
—
—
Nevertheless, recent data from the ERA-EDTA registry revealed that absolute case-specific excess mortality due to atheromatous CVD present a decreasing trend from 2007 to 2015 in patients on renal replacement therapy [ 146 ].